fenebrutinib
AssetSmall molecule
Inhibits Bruton's tyrosine kinase (BTK) to modulate B cell and myeloid cell activation.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- NF-κB signalling
- Indications
- 3
- Trials
- 0
- Developers
- 1
Indications
3Multiple sclerosis
Phase 3biopharmadive.com30 Sept 2026
Primary progressive multiple sclerosis
Phase 3pmlive.com30 Sept 2026
Relapsing multiple sclerosis
Phase 3pmlive.com30 Sept 2026
- Targets and what it contains3
- Owner and partners1
- Evidence for its targets2
- Competitors9
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 2 sources